Clinerion launches a seminar event in São Paulo to introduce cutting-edge tools and technologies for the acceleration of clinical research.
Clinerion will be running an open seminar event in São Paulo on May 15th, 2017, presenting cutting-edge techniques and technologies which can increase the speed, efficiency and competitiveness of Brazilian clinical trials. The event is supported by the Consulate General of Switzerland in São Paulo, and will take place at the official residence of the Consul General.
With the passing of the PL200 law in the Senate, Brazil is poised to become a major world player in the field of clinical research. Healthcare institutions in the country have an opportunity to get their patients access to innovative medication, earlier. Brazil, itself, has an opportunity to become a world leader for clinical trials.
Having forged a partnership with the iHealth Group in Brazil, Clinerion is now working with the major stakeholders in clinical trials in the country, including legislators, to introduce new ideas to accelerate clinical research.
During the event, a spectrum of experts and international key opinion leaders will look at the clinical research process and offer new thoughts and approaches to accelerating clinical research in Brazil, sharing use cases and discussing best practices.
Speakers will include the Honorary Consul of Switzerland, Luiz Gonzaga Coelho, representing the Consul General of Switzerland in São Paulo; and the Chairman-elect of the International Clinical Trials Network, Professor Dr. Ali Yağız Üresin. A representative of the University of Istanbul will speak on their experiences with trial recruitment.
According to the Consul General of Switzerland in São Paulo, Claudio Leoncavallo, “Switzerland is a leading place for innovation in the health sector, and is home for many international players in life sciences. In this regard, we are interested in fostering the relationship between Swiss companies and their Brazilian counterparts.”
“The time is right, for Brazil, and Clinerion is solidly behind the advancement of clinical trials in the country,” says Ulf Claesson, CEO of Clinerion. “We expect that attendees will gain a new appreciation for how they can use innovative tools and techniques to support patients and advance the research potential of the country.”
Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Recruitment System accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Key tools for Clinerion’s patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology company headquartered in Switzerland. Clinerion's solutions follow international patient privacy and data security standards.
Clinerion website: www.clinerion.com
Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem
For more information, please contact:
Le Vin Chin
Head of Marketing and Communications
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54